Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Update

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a drop of 14.6% from the February 13th total of 1,850,000 shares. Based on an average daily volume of 783,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 4.7% of the company’s shares are short sold.

Hedge Funds Weigh In On Iterum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Iterum Therapeutics during the fourth quarter worth $777,000. Apollon Financial LLC lifted its position in Iterum Therapeutics by 11.3% in the 4th quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock valued at $443,000 after acquiring an additional 25,500 shares in the last quarter. XTX Topco Ltd bought a new stake in Iterum Therapeutics in the 3rd quarter valued at $36,000. Two Sigma Investments LP bought a new stake in Iterum Therapeutics in the 4th quarter valued at $45,000. Finally, Citadel Advisors LLC bought a new stake in Iterum Therapeutics in the 4th quarter valued at $38,000. 9.21% of the stock is owned by institutional investors.

Iterum Therapeutics Price Performance

Shares of NASDAQ ITRM opened at $1.45 on Friday. The company’s fifty day moving average is $1.47 and its 200-day moving average is $1.48. The stock has a market cap of $50.14 million, a price-to-earnings ratio of -1.11 and a beta of 2.44. Iterum Therapeutics has a twelve month low of $0.81 and a twelve month high of $3.02.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.